Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin for Liver Fat in T2DM with NAFLD/NASH
NCT05644717Phase 4Recruiting
- Sponsor
- Getz Pharma
- Start
- Mar 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ertugliflozin in non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), sponsored by Getz Pharma. Started Mar 2023; status: recruiting.
02
Drugs
ertugliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05644717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644717.